Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK932121
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GSK932121 is a small molecule antimalarial drug candidate developed by GSK (GlaxoSmithKline) and Medicines for Malaria Venture. It belongs to the 4(1H)-pyridone chemical class and acts as an inhibitor of the electron transport chain in *Plasmodium falciparum* by binding to the Qi site of cytochrome bc1 (complex III). This mechanism allows it to overcome atovaquone resistance in malaria parasites. Despite its potent antimalarial activity both *in vitro* and *in vivo*, development was halted after phase I clinical trials due to cardiotoxicity concerns[4][6][7][8].
02
Targets
CYTB (Plasmodium falciparum cytochrome bc1 complex (qi site))bc1 complex (Cytochrome bc1 complex (plasmodium))
Beyond the preview
Go deeper on GSK932121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK932121.